Skip to main content

Published locations for FDA panel starts review of rosiglitazone CV data

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA panel starts review of rosiglitazone CV data

User login

  • Reset your password
  • /content/fda-panel-starts-review-rosiglitazone-cv-data
  • /familypracticenews/article/59079/acute-coronary-syndromes/fda-panel-starts-review-rosiglitazone-cv
  • /internalmedicinenews/article/59079/acute-coronary-syndromes/fda-panel-starts-review-rosiglitazone-cv
  • /clinicalendocrinologynews/article/59079/acute-coronary-syndromes/fda-panel-starts-review
  • /ecardiologynews/article/59079/acute-coronary-syndromes/fda-panel-starts-review-rosiglitazone-cv-data
  • /cardiology/article/59079/acute-coronary-syndromes/fda-panel-starts-review-rosiglitazone-cv-data
  • /endocrinology/article/59079/acute-coronary-syndromes/fda-panel-starts-review-rosiglitazone-cv-data
  • /internalmedicine/article/59079/acute-coronary-syndromes/fda-panel-starts-review-rosiglitazone-cv
  • /familymedicine/article/59079/acute-coronary-syndromes/fda-panel-starts-review-rosiglitazone-cv-data
  • /type-2-diabetes-icymi/article/59079/acute-coronary-syndromes/fda-panel-starts-review-rosiglitazone